Diabetes Management
33 articles on Diabetes Management, written by Shotlee and medically reviewed for clinical accuracy.
Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies
Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.
7 min read
GLP-1 Drugs: A New Frontier in Addiction Treatment?
Could the same medications revolutionizing weight loss and diabetes management also hold the key to treating addiction? Emerging research suggests GLP-1 receptor agonists may play a significant role.
8 min read
Beyond the Hype: Understanding the Rise of Peptide Therapy
Peptide therapy is gaining traction, with compounds like semaglutide revolutionizing weight management. But what exactly are peptides, and what are the realities behind the trending 'peptide summer'? This article delves into the science, the risks, and the future of this evolving field.
7 min read
Generic Semaglutide Launches in Canada: What Patients Need to Know
The Canadian market sees the arrival of a generic semaglutide injection, a significant development for individuals managing type 2 diabetes and seeking weight loss solutions. This launch by Dr. Reddy's Laboratories marks a new era of accessibility for this popular GLP-1 therapy.
7 min read
Understanding Insulin Resistance: Beyond Blood Sugar
Insulin resistance is a critical metabolic condition affecting blood sugar regulation and potentially impacting brain function. This comprehensive guide delves into its causes, symptoms, and the vital role of lifestyle interventions.
8 min read
Amazon Stocks Oral Ozempic Pills: Same-Day Delivery & Pricing Guide
Amazon Pharmacy is expanding access to oral GLP-1 medications like Ozempic and Wegovy through kiosks and same-day delivery. Here is everything you need to know about pricing, logistics, and managing your treatment.
7 min read
GLP-1 Medications: Understanding Ozempic, Wegovy, and Mounjaro
Celebrities and everyday individuals are increasingly discussing their experiences with GLP-1 medications such as Ozempic, Wegovy, and Mounjaro for weight management. This article delves into the science behind these popular drugs, their benefits, potential side effects, and what users can expect.
7 min read
Wegovy Sales Surge 70% After Price Cuts: What You Need to Know
Novo Nordisk's Wegovy experienced a remarkable 70% sales volume increase in April after significant price adjustments. This development highlights the growing demand for GLP-1 receptor agonists in weight management and the dynamic shifts within the pharmaceutical market.
6 min read
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
6 min read
FDA's GLP-1 Compounding Crackdown: What Patients Need to Know
The U.S. Food and Drug Administration (FDA) has announced a significant proposal to restrict the compounding of popular GLP-1 medications, including semaglutide and tirzepatide. This move aims to enhance patient safety and uphold the integrity of approved drug products. Here's a comprehensive look at what this means for individuals managing weight and diabetes.
7 min read
Generic Semaglutide Approval in Canada: What It Means for Patients
Dr. Reddy's Laboratories has achieved a significant milestone by becoming the first company to receive market authorization from Health Canada for its generic semaglutide injection. This development promises to increase access to a crucial treatment option for Canadians.
6 min read
Semaglutide NAION Risk: New Study Findings for Weight Loss Patients
A recent analysis published in JAMA Ophthalmology reveals a significant increase in NAION risk associated with semaglutide compared to SGLT2 inhibitors, though absolute risk remains low.
8 min read
GLP-1 Drugs Show New Promise in Cardiovascular Procedures
New research suggests that GLP-1 receptor agonists, known for their roles in diabetes and weight management, may offer significant cardiovascular protection for patients undergoing complex procedures like TAVR and carotid artery stenting.
7 min read
Ozempic Personality: Understanding Emotional Changes with GLP-1 Medications
Many users of GLP-1 medications like Ozempic and Wegovy report experiencing 'Ozempic personality,' a phenomenon characterized by emotional flattening and a reduced interest in formerly enjoyable activities. This article delves into what this means, potential causes, and how to navigate these changes.
8 min read
Dr. Reddy's Semaglutide Inches Closer to Canadian Market Approval
Dr. Reddy's Laboratories has announced a significant milestone in its pursuit of bringing its semaglutide injection to the Canadian market, having received Drug Identification Numbers (DINs) from Health Canada. This development signals progress in the regulatory review process and underscores the company's commitment to expanding access to this important medication.
7 min read
Ozempic and GLP-1 Drugs: Heart Benefits and Personal Realities
Thirty million Americans—one in eight—are turning to GLP-1 drugs like Ozempic for weight management and more, with data showing a 20% reduced risk of heart attacks and strokes. But what happens when the weight doesn't budge, as in 10% of users? This personal story explores the hype, realities, and broader implications of these medications.
4 min read
Ozempic Isn't a Magic Fix: Semaglutide Risks in India
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
6 min read
Retatrutide: Can This Shot Aid Weight Loss and Longevity?
Retatrutide, a promising new weight-loss injection, targets three hormone receptors to tackle obesity and diabetes head-on. Clinical trials demonstrate significant weight loss, and experts suggest it may support longevity goals too. Discover how this triple-action therapy stands out in metabolic health.
4 min read
India Issues Guidelines on GLP-1 Drugs Use, Risks, Regulations
The Government of India has issued comprehensive guidelines on GLP-1 drugs, addressing their use for type 2 diabetes and obesity, associated risks, and regulatory measures. With drugs like semaglutide and tirzepatide gaining popularity, authorities warn against unsupervised use due to serious side effects like pancreatitis. Strict surveillance ensures prescriptions only by specialists like endocrinologists.
6 min read
Ozempic Goes Generic Worldwide, But Not in U.S. Until 2030
Ozempic, the blockbuster semaglutide drug from Novo Nordisk, is set to go generic in India as early as this weekend, with China, Brazil, Turkey, and South Africa following. This could drop prices to $15 per month, opening access to millions with obesity and diabetes. Meanwhile, U.S. and Europe face delays until 2030 due to patent extensions.
5 min read
Experts Stress Holistic Approach to Semaglutide for Weight Management
At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.
6 min read
Telangana Warns on Semaglutide Misuse for Weight Loss
Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.
5 min read
Grim Effects of Stopping GLP-1s Like Ozempic, Study Finds
New research paints a stark picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. Published in BMJ Medicine, the study tracked over 333,000 adults and warns of 'metabolic whiplash.' Patients face weight regain, inflammation resurgence, and lasting scars from interruptions.
4 min read
Mounjaro Shortage Harms Patients Amid Diet Craze: Supply Crisis
A surge in dieting demand has triggered shortages of Mounjaro's 5mg starting dose, making it hard for metabolic disease patients to access treatment. Clinics in Seoul report instability until late March, as non-reimbursed status leaves supply unmanaged. Patients like Mr. A face halted therapy despite proven benefits for diabetes control and weight loss.
6 min read
Study: Ozempic-Type Drugs Like Semaglutide Can Be Made for $3/Month
A groundbreaking study shows blockbuster drugs like Ozempic and Wegovy could be manufactured at a fraction of their retail cost, potentially revolutionizing access to obesity and diabetes care. Researchers estimate semaglutide production at $3 per month for injectables, compared to hundreds today. This comes amid rising obesity in low-income countries, though experts stress lifestyle factors remain key.
4 min read
Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production
Eli Lilly is set to invest a substantial $3 billion in China over the next decade to bolster the production of its groundbreaking oral GLP-1 receptor agonist, Orforglipron. This strategic move aims to enhance supply chain capacity for a drug poised to treat type 2 diabetes and obesity.
8 min read
Slovak Singer Brigita Szelidová Loses Vocal Range After Ozempic
Renowned Slovak singer Brigita Szelidová revealed that Ozempic, prescribed for her diabetes, led to a dramatic loss of her vocal range, making even simple songs challenging. With over 30 years in the industry, her story highlights emerging concerns about GLP-1 drugs like Ozempic and Wegovy affecting performers' voices. As off-label weight loss use surges, professionals in music and opera weigh the benefits against unforeseen vocal risks.
6 min read
Unexpected Ozempic, Wegovy & Mounjaro Side Effects: Real Stories
GLP-1 drugs like Ozempic and Mounjaro promise transformative weight loss and blood sugar control, but real users reveal side effects beyond the label. From severe nausea and hair loss to surprising benefits like reduced OCD, these stories highlight the need for informed use. Learn the science, risks, and tips to manage them effectively.
5 min read
GLP-1 Kidney Risks: Study Compares Ozempic to SGLT2 Drugs
A recent Danish study in JAMA Internal Medicine highlights higher kidney risks with popular GLP-1 drugs like Ozempic compared to SGLT2 inhibitors. While GLP-1s offer weight loss benefits, understanding these findings is crucial for patients. Learn the science, risks, and how to protect your kidneys.
5 min read
GLP-1 Market Boom to $299B by 2033: Drugs & Insights
The GLP-1 analogues market is surging from $62.81B in 2024 to $299.08B by 2033, driven by rising diabetes and obesity rates. Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound lead with proven efficacy in glycemic control and weight loss. This guide breaks down the science, market trends, and what patients should know.
4 min read
Elderly Americans Abandon Weight-Loss Medications in Droves
Senior citizens in the U.S. often discontinue highly effective weight-loss medications such as GLP-1 drugs shortly after starting them, resulting in regained pounds and diminished health advantages. Side effects, high expenses, and inadequate insurance coverage frequently play key roles in this trend. Experts advocate for better coverage and ongoing research to address these challenges for older populations.
5 min read
Nature's Ozempic: Can This OTC Supplement Truly Meet Weight Loss Expectations?
Many people turn to GLP-1 drugs like Ozempic for weight loss, but cost can be a barrier. Affordable alternatives like berberine offer hope, yet experts caution against unrealistic hype. This article examines its benefits, side effects, and potential as a weight loss aid.
3 min read
Cipla Introduces Tirzepatide Drug Yurpeak for Diabetes and Obesity Treatment in India
Cipla has released Yurpeak (tirzepatide), a weekly injectable medication designed for adults managing obesity and type 2 diabetes. As the second tirzepatide brand from Lilly available in India, Yurpeak will be accessible through prescription in a user-friendly KwikPen.
3 min read